GH Research PLC Aktie News

Übereinstimmung mit der FDA hinsichtlich CMC- und Geräteplänen für Phase 3 Erfolgreicher Abschluss von GH001-HV-106 und GH001-HV-109 Phase-1-Studien Weitere Stärkung des US- und EU-Patentbestands für Mebufotenin Phase-2a-Ergebnisse bei postpartaler Depression veröffentlicht in The Journal of Clinical Psychiatry Barmittel, Zahlungsmitteläquivalente und börsennotierte Wertpapiere in Höhe von 362,...

Die finalisierte Leitlinie der US Food and Drug Administration zur Entwicklung von Psychedelika signalisiert, dass die Behörde weiterhin bereit ist, Entwickler bei der Navigation des Zulassungsprozesses zu unterstützen. Jefferies schrieb, dies könnte Unternehmen wie Compass Pathways (NASDAQ:CMPS), AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Cybin Inc. (NYSE-A:CYBN, FRA:R7E), GH Research (NASDAQ:...

DUBLIN, June 04, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS) today announced the publication of the full results from its Phase 2a trial in postpartum depression (PPD) and the acceptance of two oral presentations at the 37th World Congress of Neuropsychopharmacology (CINP 2026). The peer-reviewed article, titled “Inhaled Mebufotenin (GH001) for Adult Patients with Postpartum Depress...

Phase 2b results in TRD published in JAMA Psychiatry GH001-HV-106 study enrolment completed; doses selected for the global Phase 3 pivotal program of GH001 in TRD GH001-HV-109 US IND-opening study enrolment completed Cash, cash equivalents and marketable securities of $267.3 million as of March 31, 2026 Net cash proceeds of an additional $111.2 million from underwritten offering received in Apr...

DUBLIN, April 29, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the pricing of an underwritten offering in the United States of 6,527,779 of its ordinary shares at an offering price of $18.00 per share for total gross pr...

The White House psychedelics executive order accelerates research, clinical trials and "Right to Try" access for drugs like psilocybin, MDMA and ibogaine. The order does not change their legal status, but reinforces a federal move toward medical, evidence-based framework for other alternative medicines, like cannabis, experts say.

The only drug named in Trump's executive order is ibogaine, a psychedelic commonly used to treat depression, anxiety and PTSD among veterans. The drug, a Schedule I substance banned in the U.S., has been backed by Republicans in Texas in recent years who argue in favor of ibogaine's success with veterans.

Shares of psychedelics-related stocks climbed in early trade on Monday after US president Donald Trump signed an executive order aimed at accelerating research into psychedelic-assisted therapies and expanding patient access for certain serious mental health conditions, including post-traumatic stress disorder (PTSD) and treatment-resistant depression. The executive order, signed by Trump on Sa...